Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD

Key Takeaways

• FDA cleared Cellenkos’ IND application for Phase 1b/2a trial of CK0802 in steroid-refractory GVHD patients
• CK0802 represents first-in-class, off-the-shelf regulatory T cell therapy targeting tissue-specific treatment
• Multicenter study will evaluate safety and preliminary efficacy in patients who failed standard steroid treatment

---

Cellenkos, Inc. announced May 4, 2026, that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to begin a Phase 1b/2a clinical trial of CK0802 in patients with steroid-refractory graft-versus-host disease (GVHD).

Breakthrough Regulatory T Cell Therapy

The Houston-based clinical-stage biotechnology company is pioneering allogeneic, tissue-targeted regulatory T cell (Treg) therapies. CK0802 represents a first-in-class, off-the-shelf Treg therapy specifically designed for patients whose GVHD does not respond to standard steroid treatment.

Graft-versus-host disease occurs when transplanted immune cells attack the recipient’s healthy tissues, affecting up to 50% of patients receiving allogeneic stem cell transplants. Current treatment options remain limited, particularly for patients who develop steroid-refractory disease.

Clinical Trial Design and Implications

The upcoming multicenter, open-label study will evaluate both safety and preliminary efficacy of CK0802 in this challenging patient population. Unlike traditional approaches, CK0802’s off-the-shelf design could provide immediate treatment availability without requiring patient-specific cell manufacturing.

This FDA clearance positions Cellenkos to address a significant unmet medical need in transplant medicine. Steroid-refractory GVHD carries poor prognosis with limited therapeutic options, making novel approaches like tissue-targeted Treg therapy particularly valuable.

Market Impact and Future Outlook

The regulatory milestone represents a significant advancement in cell therapy development, potentially offering new hope for transplant patients facing treatment-resistant GVHD. The allogeneic approach could provide scalability advantages over autologous cell therapies, potentially reducing treatment costs and improving accessibility.

Cellenkos’ tissue-targeting technology differentiates CK0802 from other Treg therapies in development, potentially improving efficacy while minimizing systemic immunosuppression risks. The Phase 1b/2a trial results will be closely watched by the transplant medicine community and investors tracking the expanding cell therapy market.

---

Frequently Asked Questions

What does this FDA clearance mean for GVHD patients?

The clearance allows Cellenkos to begin testing CK0802 in patients whose GVHD doesn’t respond to steroids, potentially providing a new treatment option for this difficult-to-treat condition.

When will CK0802 be available to patients?

CK0802 is entering Phase 1b/2a trials and would need to complete clinical development and receive FDA approval before becoming commercially available, likely several years away.

How does CK0802 differ from existing GVHD treatments?

CK0802 is a first-in-class, off-the-shelf regulatory T cell therapy that targets specific tissues, unlike current treatments that broadly suppress the immune system.